FDA Approves New Prostate Cancer Imaging Agent Gozellix®
Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive ...
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc.
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind ...
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
The public offering was led by Perceptive Advisors and Nantahala Capital, with participation from other new institutional biotech investors. Company CEO George Magrath and board chairman Cam Gallagher ...
Miami Herald15h
Miami com
“For me, it represents our legacy, it represents the ability, even in the most difficult situations, to come together as a unit and make something work.” ...